Literature DB >> 33991600

The reversal of chemotherapy-induced multidrug resistance by nanomedicine for cancer therapy.

Shangui Liu1, Abdur Rauf Khan1, Xiaoye Yang1, Bo Dong2, Jianbo Ji1, Guangxi Zhai3.   

Abstract

Multidrug resistance (MDR) of cancer is a persistent problem in chemotherapy. Scientists have considered the overexpressed efflux transporters responsible for MDR and chemotherapy failure. MDR extremely limits the therapeutic effect of chemotherapy in cancer treatment. Many strategies have been applied to solve this problem. Multifunctional nanoparticles may be one of the most promising approaches to reverse MDR of tumor. These nanoparticles can keep stability in the blood circulation and selectively accumulated in the tumor microenvironment (TME) either by passive or active targeting. The stimuli-sensitive or organelle-targeting nanoparticles can release the drug at the targeted-site without exposure to normal tissues. In order to better understand reversal of MDR, three main strategies are concluded in this review. First strategy is the synergistic effect of chemotherapeutic drugs and ABC transporter inhibitors. Through directly inhibiting overexpressed ABC transporters, chemotherapeutic drugs can enter into resistant cells without being efflux. Second strategy is based on nanoparticles circumventing over-expressed efflux transporters and directly targeting resistance-related organelles. Third approach is the combination of multiple therapy modes overcoming cancer resistance. At last, numerous researches demonstrated cancer stem-like cells (CSCs) had a deep relation with drug resistance. Here, we discuss two different drug delivery approaches of nanomedicine based on CSC therapy.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CSCs therapy; Combination therapy; Multidrug resistance; Nanoparticles; P-glycoprotein (P-gp); Subcellular organelle targeting

Year:  2021        PMID: 33991600     DOI: 10.1016/j.jconrel.2021.05.012

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  8 in total

Review 1.  Recent Advances in Single Fe-Based Nanoagents for Photothermal-Chemodynamic Cancer Therapy.

Authors:  Li Zhang; Helen Forgham; Ao Shen; Ruirui Qiao; Bing Guo
Journal:  Biosensors (Basel)       Date:  2022-01-31

2.  pH/Redox/Lysozyme-Sensitive Hybrid Nanocarriers With Transformable Size for Multistage Drug Delivery.

Authors:  Zhe Liu; Dong Zhou; Lan Liao
Journal:  Front Bioeng Biotechnol       Date:  2022-04-11

Review 3.  RNA Drug Delivery Using Biogenic Nanovehicles for Cancer Therapy.

Authors:  Nuannuan Li; Yiying Sun; Yuanlei Fu; Kaoxiang Sun
Journal:  Front Pharmacol       Date:  2021-12-24       Impact factor: 5.810

Review 4.  Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies.

Authors:  Alessia Catalano; Domenico Iacopetta; Jessica Ceramella; Domenica Scumaci; Federica Giuzio; Carmela Saturnino; Stefano Aquaro; Camillo Rosano; Maria Stefania Sinicropi
Journal:  Molecules       Date:  2022-01-18       Impact factor: 4.411

Review 5.  Tumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines.

Authors:  Meng Li; Yijing Zhang; Qin Zhang; Jingchao Li
Journal:  Mater Today Bio       Date:  2022-07-15

Review 6.  Nanomedicines for Overcoming Cancer Drug Resistance.

Authors:  Tingting Hu; Hanlin Gong; Jiayue Xu; Yuan Huang; Fengbo Wu; Zhiyao He
Journal:  Pharmaceutics       Date:  2022-08-01       Impact factor: 6.525

7.  Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo.

Authors:  Yuchen Zhang; Cheukfai Li; Chenglai Xia; Keneth Kin Wah To; Zhixing Guo; Chongyang Ren; Lingzhu Wen; Fang Wang; Liwu Fu; Ning Liao
Journal:  Cell Commun Signal       Date:  2022-09-14       Impact factor: 7.525

8.  Effect of Ducrosia flabellifolia and Savignya parviflora Extracts on Inhibition of Human Colon and Prostate Cancer Cell Lines.

Authors:  Youssef Saeed Alghamdi; Osama Moseilhy Saleh; Nada Alqadri; Mutaib Mosaued Mashraqi; Omar Bahattab; Nabil Saied Awad
Journal:  Curr Issues Mol Biol       Date:  2021-10-10       Impact factor: 2.976

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.